Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: A phase I evaluation

AIDS

Volumn 16, Issue 15, 2002, Pages 2019-2025

  Stiegler, Gabriela ^a   Armbruster, Christine ^a   Vcelar, Brigitta ^a   Stoiber, Heribert ^a   Kunert, Renate ^a   Michael, Nelson L ^a   Jagodzinski, Linda L ^a   Ammann, Christoph ^a   Jäger, Walter ^a   Jacobson, Jeffrey ^a   Vetter, Norbert ^a   Katinger, Hermann ^a  

^a UNIVERSITY OF AGRICULTURAL SCIENCES   (Austria)

Author keywords

Antiviral effects; HIV therapy; HIV 1; Human monoclonal antibodies

Indexed keywords

COMPLEMENT COMPONENT C3; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LYMPHOCYTE COUNT; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VIRUS LOAD; VIRUS NEUTRALIZATION;

ADULT; ANTIBODIES, MONOCLONAL; CD4 LYMPHOCYTE COUNT; COMPLEMENT ACTIVATION; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; RNA, VIRAL; VIRAL LOAD;

EID: 0037131212     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200210180-00006     Document Type: Article

References (22)

1. Pilgrim AK, Pantaleo G, Cohen OJ, et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressve infection. J Infect Dis 1997, 176:924-932.
2. Carotenuto P, Looij D, Keldermans L, de Wolf F, Goudsmit J. Neutralizing antibodies are positively associated with CD4+ T. cell counts and T-cell function in long-term AIDS-free infection. AIDS 1998, 12:1591-1600.
3. Cecilia D, Kleeberger C, Munoz A, Giorgi IV, Zolla-Pazner S. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis 1999, 179:1365-1374.
4. Stiehm ER, Mofenson L, Zolla-Pazner S, Jackson B, Martin NL, Ammann AJ. Summary of the workshop on passive immunotherapy in the prevention and treatment of HIV infection. The Passive Antibody Workshop Participants. Clin Immunol Immunopathol 1995, 75:84-93.
5. Morand-Joubert L, Vittecoq D, Roudot-Thoraval F, et al. Virological and immunological data of AIDS patients treated by passive immunotherapy (transfusions of plasma rich in HIV-1 antibodies). Vox Sang 1997, 73:149-154.
6. Blick G, Scott WF, Crook SW, et al. Passive immunotherapy in advanced HIV infection and therapeutic plasmapheresis in asymptomatic HIV-positive individuals: a four-year clinical experience. Biotherapy 1998, 11:7-14.
7. Stiehm ER, Fletcher CV, Mofenson LM, et al. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). J Infect Dis 2000, 181:548-554.
8. Cavacini LA, Samore MH, Gambertoglio J, et al. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses 1998, 14:545-550.
9. Jacobson JM, Lowy I, Fletcher CV, et al. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis 2000, 182:326-329.
10. Purtscher M, Trkola A, Gruber G, et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994, 10:1651-1658.
11. Trkola A, Purtscher M, Muster T, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996, 70:1100-1108.
12. Mascola JR, Lewis MG, Stiegler G, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999, 73:4009-4018.
13. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nature Med 2000, 6:200-206.
14. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Med 2000, 6:207-210.
15. Armbruster C, Stiegler GM, Vcelar BA, et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 2002, 16:227-233.
16. Buchacher A, Predl R, Strutzenberger K, et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994, 10:359-369.
17. Hollinger FB, Bremer JW, Myers LE, Gold JW, McQuay L. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories. J Clin Microbiol 1992, 30:1787-1794.
18. Lew J, Reichelderfer P, Fowler M, et al. Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. J Clin Microbiol 1998, 36:1471-1479.
19. Stoiber H, Clivio A, Dierich MP. Role of complement in HIV infection. Ann Rev Immunol 1997, 15:649-674.
20. Stiegler G, Kunert R, Purtscher M, et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of Human Immunodeficiency Virus Type 1. AIDS Res Hum Retroviruses 2001, 17:1757-1765.
21. Burton DR, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027.
22. Xu W, Smith-Franklin BA, Li PL, et al. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J Hum Virol 2001, 4:55-61.